Aorto iliac Occlusive Disease Treatment Market Report with Forecast 2026 to 2035
Share With :
Aorto iliac Occlusive Disease Treatment Market Size is valued at USD 2.3 Bn in 2025 and is predicted to reach USD 3.9 Bn by the year 2035 at a 5.8% CAGR during the forecast period for 2026 to 2035.
Aorto-iliac Occlusive Disease Treatment Market Size, Share & Trends Analysis Distribution by Device Type (Endovascular Devices (Atherectomy Systems, Balloon Angioplasty Devices, Stents, and Surgical Devices), By Procedure (Endovascular Procedures, Hybrid Procedures, and Open Surgical Procedures), By End-user (Hospitals, Outpatient Facilities, and Others), and Segment Forecasts, 2026 to 2035
The goals of treating aorto-iliac occlusive disease (AIOD) are to prevent limb-threatening consequences, relieve symptoms like claudication and ischemic discomfort, and restore appropriate blood flow to the lower extremities. To address risk factors like hypertension, diabetes, and hyperlipidemia, management usually starts with conservative measures like quitting smoking, participating in organized exercise programs, and using antiplatelet and statin medications to slow the advancement of the diabetes condition.
The revascularization is necessary in patients with severe to moderate symptoms or critical limb ischemia. The minimally invasive nature of endovascular therapies, their quicker recovery times, and their positive results in appropriate lesions make them popular. One of the main drivers propelling the aorto-iliac occlusive disease treatment market's growth is the rising incidence of peripheral artery disease (PAD).
The aorto-iliac occlusive disease treatment market is expanding steadily as a result of the aging population and the rising prevalence of lifestyle-related risk factors such as obesity, diabetes, smoking, and hypertension. One of the main causes of lower-limb ischemia is aorto-iliac occlusive disease, and since this condition is diagnosed more frequently, there is a growing need for efficient treatment.
The acceptance of medicinal therapy, endovascular therapies, and surgical revascularization techniques has accelerated due to early detection made possible by improvements in diagnostic imaging and increased awareness among patients and doctors. Additionally, advancements in vascular care accessibility and healthcare infrastructure are fostering the aorto-iliac occlusive disease treatment market growth in both developed and developing nations.
The aorto-iliac occlusive disease treatment market is being greatly driven by technological developments in minimally invasive endovascular therapies, such as angioplasty balloons, bare-metal and drug-eluting stents, and coated stent grafts.
Compared to open surgery, these treatments are becoming more and more popular since they need fewer hospital stays, have fewer procedural risks, and require less recovery time. The use of innovative treatment modalities is also being encouraged by rising healthcare costs and advantageous payment systems in a number of nations. However, the high cost of cutting-edge endovascular devices, the scarcity of qualified vascular experts, and the dangers associated with procedures in patients with serious comorbidities are limiting the aorto-iliac occlusive disease treatment market's expansion.
• Medtronic
• Cook
• BD
• Bentley InnoMed
• Boston Scientific Corporation
• W. L. Gore & Associates, Inc.
• Terumo Corporation
• Scitech Medical
• Abbott
• iVascular
• Getinge AB
• Biotronik SE & Co KG
Peripheral artery disease (PAD), which frequently affects the aorto-iliac arteries, is becoming more common as more people suffer from lifestyle-related illnesses like diabetes, high blood pressure, and obesity. The American Heart Association estimates that peripheral artery disease affects 200 million people globally. Over time, these medical conditions damage blood vessels, increasing a person's risk of significant artery blockages. Because of this, more people are being diagnosed with aorto-iliac occlusive disease, which is increasing the need for efficient treatment alternatives. Improvements in PAD awareness and early detection have resulted in prompt medical therapies. Healthcare providers and manufacturers of medical devices are being pushed by this trend to increase the number of treatment options available for these illnesses.
The high cost of sophisticated endovascular devices and intricate surgical procedures is one of the main barriers to the aorto-iliac occlusive disease treatment market. Costly equipment, specialized operating rooms, and highly qualified vascular surgeons or interventional radiologists are needed for operations like hybrid revascularization, angioplasty with drug-eluting or coated stents, and stent graft systems. These expenses greatly raise the total cost of treatment, which limits access to sophisticated therapies, especially in low- and middle-income nations. The hospitals are further deterred from implementing modern technologies by the restricted or uneven payment for specific endovascular procedures in some areas.
The endovascular procedures segment held the largest share in the aorto-iliac occlusive disease treatment market in 2025 because of its increasing recognition as the primary therapy for aorto-iliac occlusive disease. These techniques' less intrusive nature enables quicker return to normal activities, shorter hospital stays, and less post-operative problems. Because angioplasty and stenting are repeatable, affordable, and have a positive risk-benefit profile—especially in patients with comorbidities—doctors like them. Additionally, increasing access to cath laboratories in metropolitan hospitals and extensive training in endovascular procedures have increased procedure volumes. Their quick incorporation into standard practice has also been facilitated by ongoing clinical trials and advantageous reimbursement regulations.
In 2025, the hospitals segment dominated the aorto-iliac occlusive disease treatment market. To manage complex aorto-iliac occlusive disease, hospitals are progressively adding sophisticated and minimally invasive treatments to their treatment portfolios. For instance, NYU Langone Health has adopted minimally invasive techniques, including balloon angioplasty with stenting and atherectomy. Because these procedures are carried out under local anesthesia, patients can frequently return home the same day, which shortens hospital stays and speeds up recovery. Additionally, complex aorto-iliac reconstructions are supported by the availability of hybrid operating rooms, vascular intensive care units, and round-the-clock specialized care.
The aorto-iliac occlusive disease treatment market was dominated by North America region in 2024 because of early diagnosis methods, robust reimbursement mechanisms, and the extensive use of modern endovascular procedures. Patients now have easier access to efficient therapy because of a strong healthcare system and a large number of vascular specialists. Furthermore, early management and improved results have resulted from greater screening for high-risk patients and growing awareness of peripheral artery disease.
Additionally, a high rate of new medical device adoption and continuous clinical research have contributed to consistent growth. Faster introduction of novel solutions is ensured by ongoing investments in vascular research and development, as well as robust regulatory support for device approvals. Leadership in this area has also been bolstered by favorable insurance policies and the increasing need for outpatient vascular care.
March 2025: Balloon angioplasty, particularly in the femoro-popliteal and infra-popliteal segments, is still a key treatment for lower extremity PAD, according to the Washington Healthcare Authority. The study highlighted how it can be used to improve blood flow and preserve limbs, indicating that drug-coated balloon technologies are becoming more widely used.
January 2024: The NMPA approved Zylox-Tonbridge Medical Technology Co., Ltd.'s ZYLOX Peripheral Venous Stent System for use in treating pelvic and lower limb venous diseases brought on by iliac vein compression.
| Report Attribute | Specifications |
| Market size value in 2025 | USD 2.3 Bn |
| Revenue forecast in 2035 | USD 3.9 Bn |
| Growth Rate CAGR | CAGR of 5.8% from 2026 to 2035 |
| Quantitative Units | Representation of revenue in US$ Bn and CAGR from 2026 to 2035 |
| Historic Year | 2022 to 2025 |
| Forecast Year | 2026-2035 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | Device Type, Procedure, End-user, and By Region |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; Southeast Asia; South Korea; Southeast Asia |
| Competitive Landscape | Medtronic, Cook, BD, Bentley InnoMed, Boston Scientific Corporation, W. L. Gore & Associates, Inc., Terumo Corporation, Scitech Medical, Abbott, iVascular, Getinge AB, and Biotronik SE & Co KG. |
| Customization Scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Geographic competitive landscape. |
| Pricing and Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
This study employed a multi-step, mixed-method research approach that integrates:
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Secondary data for the market study was gathered from multiple credible sources, including:
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Primary interviews for this study involved:
Interviews were conducted via:
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
This ensured that the dataset used for modelling was clean, robust, and reliable.
The bottom-up approach involved aggregating segment-level data, such as:
This method was primarily used when detailed micro-level market data were available.
The top-down approach used macro-level indicators:
This approach was used for segments where granular data were limited or inconsistent.
To ensure accuracy, a triangulated hybrid model was used. This included:
This multi-angle validation yielded the final market size.
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Given inherent uncertainties, three scenarios were constructed:
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.